CNC
CENTENE CORP
NYSE · Healthcare · Medical - Healthcare Plans · US
$74.22
+9.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 194.7B | 194.8B | 163.1B | 154.0B | 144.5B |
| Cost of Revenue | 162.7B | 170.9B | 146.2B | 136.7B | 127.9B |
| Gross Profit | 31.9B | 23.8B | 16.8B | 17.3B | 16.7B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 13.5B | 13.3B | 12.4B | 12.6B | 11.6B |
| General & Admin Expense | 10.4B | 13.3B | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 17.3B | 18.2B | 1.3B | 1.8B | 3.7B |
| Total Operating Expenses | 30.8B | 31.5B | 13.7B | 14.4B | 15.3B |
| Cost and Expenses | 193.5B | 202.4B | 159.9B | 151.1B | 143.2B |
| Operating Income (EBIT) | 1.2B | (7.6B) | 3.2B | 2.9B | 1.3B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 634.0M | 678.0M | 702.0M | 725.0M | 665.0M |
| Net Interest Income | (634.0M) | (678.0M) | (702.0M) | (725.0M) | (665.0M) |
| Other Non-Op Income/Expense | 731.4M | 890.4M | 1.1B | 668.0M | 644.0M |
| Non-Operating Income (excl Interest) | (1.4B) | (1.2B) | (1.8B) | (1.4B) | (1.3B) |
| EBT (Pre-Tax Income) | 1.9B | (6.7B) | 4.3B | 3.6B | 2.0B |
| Income Tax Expense | 459.0M | (51.0M) | 963.0M | 899.0M | 760.0M |
| Bottom Line | |||||
| Net Income | 1.5B | (6.7B) | 3.3B | 2.7B | 1.2B |
| Earnings from Cont. Ops | 1.5B | (6.7B) | 3.3B | 2.7B | 1.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.5B | (6.7B) | 3.3B | 2.7B | 1.2B |
| Per Share | |||||
| Basic EPS | $2.96 | ($13.61) | $6.33 | $4.97 | $2.09 |
| Diluted EPS | $2.92 | ($13.62) | $6.31 | $4.95 | $2.07 |
| Revenue Per Share | $394.00 | $396.64 | $312.52 | $283.44 | $251.30 |
| Shares | |||||
| Basic Shares Outstanding | 494.1M | 491.1M | 521.8M | 543.3M | 575.2M |
| Diluted Shares Outstanding | 494.1M | 491.1M | 523.7M | 545.7M | 582.0M |
| Profitability Metrics | |||||
| EBITDA | 3.8B | (5.1B) | 6.2B | 5.6B | 4.2B |
| D&A | 1.2B | 1.3B | 1.2B | 1.3B | 1.6B |
| EBIT | 2.6B | (6.4B) | 5.0B | 4.3B | 2.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026